A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom
scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact
Scale {GGISIS}) in assessing GI tolerability in adult subjects with RRMS after administration
of ALKS 8700 or Dimethyl Fumarate (DMF) in Part A, to compare the GI tolerability of ALKS
8700 and DMF in adult subjects with RRMS using IGISIS and GGISIS in Part B, and to Evaluate
the safety and tolerability of ALKS 8700 in adult subjects with RRMS in Parts A and B.